Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546022 | 1.00 | CCR5 (0.39) | CCR5MLNRHTR2AHTR2CPOLB | |
| SCHEMBL4101550 | 0.81 | CCR5 (0.35) | CCR5MLNRHTR2AHTR2CCNR2 | |
| SCHEMBL4101554 | 0.81 | CCR5 (0.35) | CCR5MLNRHTR2AHTR2CCNR2 | |
| SCHEMBL1546019 | 0.81 | DRD2 (0.35) | CCR5MAPT | |
| SCHEMBL1546249 | 0.74 | MLNR (0.42) | MLNRHTR2AHTR2CPOLBCNR2 | |
| SCHEMBL1546243 | 0.74 | MLNR (0.42) | MLNRHTR2AHTR2CPOLBCNR2 | |
| SCHEMBL1545190 | 0.73 | ADRA2A (0.37) | — | |
| SCHEMBL1545188 | 0.73 | ADRA2A (0.37) | — | |
| SCHEMBL1544809 | 0.73 | NR1H2 (0.42) | — | |
| SCHEMBL1545283 | 0.73 | ADRA2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311801-A1 | 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-7759397-B2 | 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20080318996-A1 | 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO.KG A CORPORATION | 2008-12-25 | — | — | US | disclosed |
| EP-1807392-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006040177-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318996-A1 | 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADORA3, NPR3, SLC6A3 | CCR5 1109/4885MLNR 590/4885HTR2A 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.